Morgan Stanley Dbv Technologies S.A. Transaction History

Morgan Stanley

  • $1.35 Trillion
  • Q3 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Oct 17, 2024
BUY
$0.75 - $0.95 $474,347 - $600,839
632,463 New
632,463 $474,000
Q1 2024

Aug 16, 2024
SELL
$0.75 - $0.95 $20,447 - $25,899
-27,263 Reduced 4.13%
632,463 $474,000
Q1 2024

May 15, 2024
SELL
$0.75 - $0.95 $20,447 - $25,899
-27,263 Reduced 4.13%
632,463 $474,000
Q4 2023

Aug 16, 2024
BUY
$0.7 - $1.33 $461,808 - $877,435
659,726 New
659,726 $626,000
Q4 2023

Feb 13, 2024
BUY
$0.7 - $1.33 $94,521 - $179,591
135,031 Added 25.74%
659,726 $626,000
Q3 2023

Nov 15, 2023
SELL
$1.3 - $1.88 $10,479 - $15,154
-8,061 Reduced 1.51%
524,695 $713,000
Q2 2023

Aug 14, 2023
BUY
$1.42 - $2.23 $11,049 - $17,351
7,781 Added 1.48%
532,756 $1.01 Million
Q1 2023

May 15, 2023
BUY
$1.28 - $1.73 $37,295 - $50,407
29,137 Added 5.88%
524,975 $887,000
Q4 2022

Feb 14, 2023
SELL
$1.16 - $1.8 $41,668 - $64,657
-35,921 Reduced 6.76%
495,838 $758,000
Q3 2022

Nov 14, 2022
SELL
$1.77 - $2.76 $79,260 - $123,592
-44,780 Reduced 7.77%
531,759 $941,000
Q2 2022

Oct 27, 2022
BUY
$1.15 - $3.25 $18,880 - $53,358
16,418 Added 2.93%
576,539 $1.47 Million
Q2 2022

Aug 15, 2022
BUY
$1.15 - $3.25 $18,880 - $53,358
16,418 Added 2.93%
576,539 $1.47 Million
Q1 2022

Oct 27, 2022
SELL
$1.22 - $1.77 $20,029 - $29,059
-16,418 Reduced 2.85%
560,121 $890,000
Q1 2022

May 13, 2022
SELL
$1.22 - $1.77 $398,882 - $578,706
-326,953 Reduced 36.86%
560,121 $890,000
Q4 2021

Feb 14, 2022
SELL
$1.39 - $5.58 $769,447 - $3.09 Million
-553,559 Reduced 38.42%
887,074 $1.42 Million
Q3 2021

Nov 15, 2021
BUY
$4.71 - $5.92 $6.79 Million - $8.53 Million
1,440,633 New
1,440,633 $7.06 Million

Others Institutions Holding DBVT

# of Institutions
2
Shares Held
3.2K
Call Options Held
0
Put Options Held
0
View Full List

About DBV Technologies S.A.

DBVT Quotes by TradingView
  • Ticker DBVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,776,992
  • Market Cap $745M
  • Description
  • DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...
More about DBVT
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email